Anti‐Calcitonin Gene‐Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. (7th November 2018)

• Record Type: Journal Article
• Authors: Tepper, Stewart J.
• Is Part Of: Headache. Volume 58(2018)Supplement 3
• Page Start: 276
• Page End: 290
• Publication Date: 2018-11-07
• Subjects: calcitonin gene‐related peptide -- CGRP -- gepants -- monoclonal antibodies -- migraine -- cluster headache; Headache -- Periodicals; Headache -- Periodicals; 616.8491
• DOI: 10.1111/head.13417
• Languages: English
• ISSNs: 0017-8748

Abstract

Abstract : Objective: To briefly update and correct the available data on anti‐calcitonin gene‐related peptide (CGRP) therapies for headache since the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Background: CGRP is a target for primary headache therapies. Methods: The author briefly reviews the new data and publications on gepants and anti‐CGRP and anti‐CGRP receptor monoclonal antibodies since the writing of his previous review in May 2018, with an emphasis on data provided at the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Results: The US Food and Drug Administration (FDA) approved erenumab‐aooe, an anti‐CGRP receptor monoclonal antibody, for the prevention of migraine on May 17, 2018. On September 14, 2018, the FDA approved fremanezumab‐vfrm and on September 26, 2018, the FDA approved galcanezumab‐gnlm, both anti‐CGRP ligand monoclonal antibodies for the prevention of migraine. Galcanezumab showed effectiveness in preventing episodic cluster headache as well, although has not yet been submitted to the FDA for this indication. Both galcanezumab and fremanezumab failed to prevent chronic cluster headache. Eptinezumab will likely be submitted to the FDA for prevention of migraine later in 2018. Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the FDA for this indication. A press release with data on the effectiveness of daily atogepant in migraine prevention provides some details. An announcement at the meeting suggests daily rimegepant will be tested for prevention as well. Conclusions: The development of anti‐CGRP therapies opens a new era in the acute and preventive treatment of primary headache disorders.